{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:59:25Z","timestamp":1775685565413,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euo.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:32:01Z","timestamp":1766129521000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Value of Prior Non\u2013muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-8351","authenticated-orcid":false,"given":"Elisabeth","family":"Grobet-Jeandin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott","family":"Diamant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"De Olivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9o","family":"Harber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hanquiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Chatain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Vordos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Duquesne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihnea Bogdan","family":"Borz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Verhoest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Mauger","family":"De Varennes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Surlemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Ghenassia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Lebacle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Beniac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"L\u00e9on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayek","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szostek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Calleris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.11.006_b0005","unstructured":"IARC, Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021. https:\/\/gco.iarc.fr\/today\/online-analysis-table."},{"key":"10.1016\/j.euo.2025.11.006_b0010","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.006_b0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bju.12403","article-title":"Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis","volume":"113","author":"Breau","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.11.006_b0035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bju.13146","article-title":"Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy","volume":"117","author":"Moschini","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.11.006_b0040","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/j.clgc.2018.04.004","article-title":"History of non-muscle-invasive bladder cancer may have a worse prognostic impact in cT2-4aN0M0 bladder cancer patients treated with radical cystectomy","volume":"16","author":"Kayama","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.11.006_b0045","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2020.09.006","article-title":"Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: results from a large multicenter study","volume":"39","author":"Nouhaud","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.006_b0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.urology.2007.05.008","article-title":"Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors","volume":"70","author":"T\u00fcrk\u00f6lmez","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.11.006_b0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejso.2009.11.012","article-title":"Survival after cystectomy for invasive bladder cancer","volume":"36","author":"de Vries","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.euo.2025.11.006_b0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000350232","article-title":"Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy","volume":"91","author":"Aziz","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2025.11.006_b0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2490-13-23","article-title":"The natural history of secondary muscle-invasive bladder cancer","volume":"13","author":"Hidas","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clgc.2013.11.014","article-title":"EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer","volume":"12","author":"May","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.11.006_b0075","doi-asserted-by":"crossref","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202\u20135; discussion 205\u20136.","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"10.1016\/j.euo.2025.11.006_b0080","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171\u20137.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"10.1016\/j.euo.2025.11.006_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2022.05.001","article-title":"The impact of primary versus secondary muscle-invasive bladder cancer at diagnosis on the response to neoadjuvant chemotherapy","volume":"41","author":"D\u2019Andrea","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.11.006_b0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(05)64047-5","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"S\u00e1nchez-Ortiz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","article-title":"Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes","volume":"2","author":"Boeri","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.11.006_b0105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.11.006_b0110","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.11.006_b0115","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2025.11.006_b0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0125","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.11.006_b0130","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2025.11.006_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.euo.2025.11.006_b0140","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/cancers13102496","article-title":"Differential prognosis and response of de novo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis","volume":"13","author":"Pones","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.11.006_b0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijsu.2018.02.049","article-title":"Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: a systematic review and meta-analysis","volume":"52","author":"Chen","year":"2018","journal-title":"Int J Surg"},{"key":"10.1016\/j.euo.2025.11.006_b0150","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","article-title":"Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Ge","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2025.11.006_b0155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijms.49228","article-title":"Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: an updated meta-analysis","volume":"18","author":"Zheng","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.euo.2025.11.006_b0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urology.2022.06.012","article-title":"Comparing pathologic and survival outcomes between primary and secondary muscle invasive bladder cancer when treated by radical cystectomy with or without neoadjuvant chemotherapy","volume":"168","author":"Benidir","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.11.006_b0165","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after bacillus Calmette-Gu\u00e9rin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0170","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2025.11.006_b0175","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0180","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.11.006_b0185","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.11.006_b0190","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.11.006_b0195","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:56:35Z","timestamp":1775681795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2588931125002949"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.11.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive Value of Prior Non\u2013muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}